It is too early, but the first phase data of AskBio’s adeno-associated vector (AAV) treatment indicates severe heart failure in the genetic capacity to deal with cardiovascular disease.
The highest value, presented at the 25th annual meeting of the American Society of Gene and Cell Therapy, was emphasized on both sides. First, and most notably, the drug has been 30 times significantly higher in human hearts than in pigs’ hearts by one-tenth of the dose. In an interview with Fierce Biotech, AskBio’s head of cardiology Roger Hajjar, M.D., said the findings “shocked” his team. Often, scientists are aware of the details of animals that translate directly, let alone better ones, from humans because of increased complexity.
“Furthermore, we have recently received data that will also show that the cellular effects on the biology of heart failure were positively affected in this biopsy sample,” Hajjar said. “That was strong evidence that, you know, it was not just a discovery, but it really changed the science of the heart cell.”
